Using Omnidirectional Virtual Reality and Treadmill Training for Chronic Stroke (PROVE)

December 9, 2025 updated by: Adria Quigley, Nova Scotia Health Authority

PROVE-VR: A Pilot Randomized Trial Using Omnidirectional Virtual Reality and Treadmill Training for Chronic Stroke Survivors

The primary objective of this pilot randomized controlled trial (RCT) is to test the feasibility (consent rate, retention rate, participant burden, adherence, technical issues, safety) and usability (system usability scale, SUS) of Omnidirectional treadmill Virtual Reality training (omni-VR) among chronic stroke survivors. Our secondary objective is to (1) estimate the extent to which cognition, brain activation during a dual task activity, walking ability, and dynamic balance change after 3 months of training among intervention participants (omni-VR) and traditional exercise controls, and (2) estimate the extent to which health-related quality of life and motivation co-evolve with our secondary outcomes.

Researchers will compare the intervention group and control group to evaluate the impact of omni-VR on cognition and physical function among stroke survivors.

Participants will:

  • undergo a 45-minute training session 3 times per week for 12 weeks
  • intervention group: omni-VR
  • control group: traditional exercise program (strengthening and walking activities)

Study Overview

Detailed Description

Mounting data indicates that cognition plays a role in complex walking and balance. However, conventional intervention methods lack a sufficient incentive to encourage participants to adhere to the treatment. Further, it is difficult to provide a substantial amount of treatment to induce cortical reorganization.

Virtual reality or VR (a computer-generated simulation of 3-dimensional virtual environments that reacts in real time to the user's actions) has been introduced to neurorehabilitation to promote improvements in walking ability, balance, and cognition. It has also been demonstrated to be effective in improving motivation among stroke survivors and augmenting neuroplasticity.

Omnidirectional treadmill technology can be integrated with VR to allow for fully immersive rehabilitation. This novel and innovative technology mimics real-world environments and maximizes challenging cognitive and physical dual-tasking and balance activities while maintaining patient safety. However, no randomized trials have evaluated the impact of omnidirectional treadmill VR (Omni-VR) on cognitive and physical function among stroke survivors.

Therefore, our study aims to test the feasibility and usability of the Omni-VR. This pilot randomized control trial will also be the first study to test the feasibility and effect of a fully-immersive active omni-VR system among chronic stroke survivors

Study Type

Interventional

Enrollment (Estimated)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Nova Scotia
      • Halifax, Nova Scotia, Canada, B3H 4K4
        • Recruiting
        • Nova Scotia Rehabilitation & Arthritis Centre
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria

  • Age ≥ 18
  • Stroke ≥ 6 months ago (confirmed with chart review)
  • Living within 50 km of Halifax, Nova Scotia
  • Functional Ambulation Category of 3 or greater on a scale of 0-5, to ensure the participant is able to walk with supervision or independently. This criterion was selected to ensure participants could safely participate in the intervention.
  • Ability to participate in low-moderate intensity aerobic or strengthening exercise for ≥ 15 minutes to ensure participants can tolerate intervention sessions of 30-45 minutes, with activity breaks, in keeping with previous stroke rehabilitation studies.
  • No uncorrected visual deficits or spatial neglect
  • No cardiovascular, orthopedic, or neurological diseases other than stroke impacting walking or balance
  • Can follow simple instructions
  • Score of < 27 on the adapted Motion Sickness Susceptibility Scale-Short based on established normative values indicating more than moderate susceptibility to motion sickness.

Exclusion Criteria:

  • Unstable serious medical condition
  • Resting blood pressure >180/100mmHg
  • History of abnormal untreated heart rhythm
  • Pregnancy
  • Condition limiting ability to complete or tolerate the exercises without major program modifications (e.g., chronic low back pain)
  • Serious comorbid condition that would affect participation in the intervention (e.g., active cancer, severe heart disease)
  • Severe loss of hearing or speech that would preclude VR use
  • Participant weight more than 264 lbs (weight limit for Virtualizer Elite 2 treadmill)
  • Participating in another formal lower limb exercise program > 1 day per week
  • History of QT prolongation or using potential QT prolonging drugs

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Omni-VR group
20 participants will undergo 45-minute training sessions 3 times per week for 12 weeks using omnidirectional virtual reality and treadmill training.
Omni-VR forest scenario developed by our team involving real-life dual task walking and dynamic balance activities (ie. stepping over obstacles, and managing distractions) will be used for treatment group.
Active Comparator: Control group
10 participants will undergo 45-minute traditional physiotherapy training sessions including lower limb strengthening and unidirectional treadmill training 3 times per week for 12 weeks.
A traditional exercise program including strengthening and unidirectional treadmill activities for the same duration will be completed in control group.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Retention rate
Time Frame: 12 weeks (study completion)
Retention rate is the percentage of participants who complete the 12-week intervention. The investigators expect a retention rate of 80% for the intervention group.
12 weeks (study completion)
Usability of the Omnidirectional Treadmill and Virtual Reality Game
Time Frame: 12 weeks (study completion)
Usability will be assessed by System Usability Scale (SUS) out of 100 points. The investigators expect a SUS score of 71 or higher among all participants.
12 weeks (study completion)
Participant burden
Time Frame: Baseline and 12 weeks (study completion)
Participant burden will be measured by the percentage of participants finishing assessments in 100 minutes or less. The investigators anticipate at least 85% of participants completing assessments within the time limit.
Baseline and 12 weeks (study completion)
Adherence
Time Frame: 12 weeks (study completion)
Adherence will be measured by the exercise session attendance. The investigators expect the treatment group to attend 70% or more of the sessions.
12 weeks (study completion)
Consent rate
Time Frame: Baseline
Consent rate is the percentage of eligible individuals who participate. The investigators expect a consent rate of at least 40%.
Baseline
Equipment downtime
Time Frame: 12 weeks (study completion)
The investigators will record any treadmill downtime due to VR technical issues. The targets are zero significant downtime in 85% of sessions.
12 weeks (study completion)
Equipment safety
Time Frame: 12 weeks (study completion)
The investigators will record any serious adverse events related to the study. The target is no serious adverse events related to the study
12 weeks (study completion)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Dynamic balance
Time Frame: Baseline and 12 weeks (study completion)
The investigators will measure the static sway with feet together using omni-VR system and use MINI-BESTest to measure the dynamic balance.
Baseline and 12 weeks (study completion)
Cognitive function
Time Frame: Baseline and 12 weeks (study completion)
The investigators will use the Computerized MoCA [Montreal Cognitive Assessment] Duo to evaluate participants' cognitive function.
Baseline and 12 weeks (study completion)
Executive Function
Time Frame: Baseline and 12 weeks (study completion)
The investigators will use the Dimensional Change Card Sort to evaluate participants' executive function.
Baseline and 12 weeks (study completion)
Working memory
Time Frame: Baseline and 12 weeks (study completion)
The investigators will use the List Sorting Working Memory Test to evaluate participants' working memory.
Baseline and 12 weeks (study completion)
Brain activation in prefrontal and premotor cortices
Time Frame: Baseline and 12 weeks (study completion)
Brain activation using fNIRS [Functional near-infrared spectroscopy] in the prefrontal and premotor regions of interest during a single task (steady-state omnidirectional treadmill walking) and two cognitive-physical dual-task activities (simple dual-task: steady-state omnidirectional treadmill walking while repeating the same word and complex dual-task: steady-state omnidirectional treadmill walking while performing a verbal fluency test)
Baseline and 12 weeks (study completion)
Walking Speed
Time Frame: Baseline and 12 weeks (study completion)
Walking speed using VIVE trackers on omnidirectional treadmill and overground
Baseline and 12 weeks (study completion)
Step cadence
Time Frame: Baseline and 12 weeks (study completion)
The investigators will evaluate step cadence using the VIVE trackers.
Baseline and 12 weeks (study completion)
Step width
Time Frame: Baseline and 12 weeks (study completion)
The investigators will evaluate step width using the VIVE trackers.
Baseline and 12 weeks (study completion)
Step length
Time Frame: Baseline and 12 weeks (study completion)
The investigators will evaluate step length using the VIVE trackers.
Baseline and 12 weeks (study completion)

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Motivation of participant
Time Frame: 12 weeks (study completion)
The investigators will measure motivation by intrinsic motivation inventory. Higher scores indicate better results.
12 weeks (study completion)
Health-related quality of life of participant
Time Frame: Baseline and 12 weeks (study completion)
The investigators will measure health-related quality of life by the Stroke Impact Scale-3.0. Higher scores indicate better results.
Baseline and 12 weeks (study completion)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 28, 2025

Primary Completion (Estimated)

August 6, 2026

Study Completion (Estimated)

September 6, 2026

Study Registration Dates

First Submitted

June 20, 2024

First Submitted That Met QC Criteria

July 3, 2024

First Posted (Actual)

July 10, 2024

Study Record Updates

Last Update Posted (Actual)

December 16, 2025

Last Update Submitted That Met QC Criteria

December 9, 2025

Last Verified

December 1, 2025

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stroke

Clinical Trials on Omnidirectional Virtual Reality and Treadmill Training

Subscribe